![Klaas Poelstra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Klaas Poelstra
Corporate Officer/Principal bei University of Groningen
Aktive Positionen von Klaas Poelstra
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Groningen | Corporate Officer/Principal | 21.08.2009 | - |
Karriereverlauf von Klaas Poelstra
Ehemalige bekannte Positionen von Klaas Poelstra
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | - |
Gründer | 21.08.2009 | - |
Statistik
International
Niederlande | 3 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Börse
- Insiders
- Klaas Poelstra
- Erfahrung